Biocept Announces Agreement With Agiomix FZ-LLC For Target Selector Liquid Biopsy Kits

Agiomix plans to validate Biocept's Target Selector™ platform in its molecular laboratory for the detection and monitoring of tumor biomarkers

San Diego, CA /PRNewswire/ - Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy solutions, announces that it has entered into an agreement with Agiomix FZ-LLC ("Agiomix"), a provider of genomics sample and bioinformatics services to customers around the world for both research and clinical applications. Under the agreement, Agiomix plans to validate Biocept's patented and proprietary liquid biopsy technology in order to perform testing for the detection of tumor biomarkers. The testing will be performed in Agiomix's UAE-based diagnostics laboratory and will be validated to ensure comparability of results achieved in Biocept's San Diego-based CLIA-certified and CAP-accredited laboratory. Subject to validation, Agiomix will purchase Biocept's liquid biopsy kits for use in its laboratory to test samples received from the Middle East, Africa, and Asia.

"At Agiomix, our focus is to provide tumor biomarker testing services to support the initiatives of global bio-therapeutics companies that are bringing leading-edge targeted cancer therapies to emerging markets, and therefore we are dedicated to bringing the best-in-class liquid biopsy technologies into our laboratory," said John Clarkson PhD, CEO of Agiomix. "We are pleased to enter into this agreement, which will allow us to offer Biocept's liquid biopsy solutions to our customers."

"We recently launched our liquid biopsy kit business, and are looking forward to working with Agiomix in their growing markets as our first Target Selector™ kit customer," said Michael Nall, President and CEO of Biocept. "Our strategy is to enable molecular laboratories around the world to exclusively license and utilize our technologies, including test kits and blood collection tubes, in specific regions as we seek to create a leading global brand in the liquid biopsy market."

About Agiomix
Agiomix has a mission to bring next generation genomics to emerging markets. Agiomix aims to provide its customers with a wide array of genomics sample and bioinformatics services for research and clinical applications. Its team of experts works very closely with customers to insure success of their research projects and collaborates with its clinical partners to enable their laboratories to offer unparalleled clinical genomics services to patients. Agiomix distinguishes itself from other providers by being closer to customers in emerging markets with focus on the Middle East, Africa and Asia. Agiomix services range from consultations on research projects, computational and facility requirements, to testing samples for research and diagnostics purposes. For additional information, please visit https://agiomix.com.

About Biocept
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). Biocept also markets research use only (RUO) kits, intended for customers throughout the world to utilize the Company's Target Selector™ technology. With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to Agiomix's ability to validate our liquid biopsy technology, whether Agiomix will purchase our liquid biopsy kits and our ability to execute our strategy to enable molecular laboratories around the world to exclusively license and utilize our technologies, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.